GAMMADELTA THERAPEUTICS
GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy.
GAMMADELTA THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics Therapeutics
Founded:
2016-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.gammadeltatx.com
Total Employee:
51+
Status:
Closed
Contact:
+44 (0207) 6911122
Total Funding:
100 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS Person Schema Gravatar Profiles Amazon Route 53 DMARC AWS Global Accelerator
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Carbylan Therapeutics
Carbylan Therapeutics was founded in 2004
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
ieso
Transforming mental healthcare by unlocking the power of clinical data
Imutex
Imutex, a startup with a Phase IIa-ready universal flu vaccine.
Mavalon Therapeutics
Mavalon is developing drugs to stop the progression of Parkinson's disease.
VIVAN Therapeutics
VIVAN Therapeutics is a company pioneering personalized cancer therapeutics using a new assay technology.
Orbus Therapeutics
Orbus Therapeutics is dedicated to developing products that treat rare diseases.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
StemSight
StemSight is a cell therapy startup developing novel treatments for blindness operating in Tampere, Finland.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Stromal Therapeutics
Stromal Therapeutics is the biotechnological spin-off from the Kantonsspital St.Gallen.
Treos Bio
Treos Bio, Inc. develops precision cancer immunotherapies tailored to patients' genetics.
Current Advisors List
Board_member
Current Employees Featured
Sandra Van Wetering VP Process Science and Manufacturing @ GammaDelta Therapeutics
VP Process Science and Manufacturing
2020-08-01
Adrian Hayday Co-Founder @ GammaDelta Therapeutics
Co-Founder
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-05-31 | Lymphact | Lymphact acquired by GammaDelta Therapeutics | N/A |
Investors List
Abingworth
Abingworth investment in Venture Round - GammaDelta Therapeutics
Takeda Ventures
Takeda Ventures investment in Venture Round - GammaDelta Therapeutics
Cancer Research Horizons
Cancer Research Horizons investment in Seed Round - GammaDelta Therapeutics
King's College London
King's College London investment in Seed Round - GammaDelta Therapeutics
The Francis Crick Institute
The Francis Crick Institute investment in Seed Round - GammaDelta Therapeutics
Abingworth
Abingworth investment in Seed Round - GammaDelta Therapeutics
Official Site Inspections
http://www.gammadeltatx.com Semrush global rank: 4.54 M Semrush visits lastest month: 2.33 K
- Host name: afe41c95a9e82f02c.awsglobalaccelerator.com
- IP address: 76.223.3.151
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "GammaDelta Therapeutics"
GammaDelta Therapeutics - Crunchbase Company …
Sep 16, 2016 Contact Email info@gammadeltatx.com Phone Number +44 (0207) 6911122 GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious …See details»
GammaDelta Therapeutics - LinkedIn
GammaDelta Therapeutics | 6,384 followers on LinkedIn. GammaDelta Therapeutics is a UK headquartered biotechnology company founded upon world-class academic research conducted by Professor Adrian ...See details»
GammaDelta Therapeutics Company Overview, Contact Details
Oct 11, 2018 | gammadeltatx.com GammaDelta Therapeutics Ltd hired Michael Koslowski on Jun 10th '18. GammaDelta Therapeutics Ltd, an emerging biotech company developing novel …See details»
GammaDelta Therapeutics - VentureRadar
"GammaDelta Therapeutics aims to harness the unique properties of ?d T cells to improve patient outcomes and survival rates among patients with haematological malignancies and solid …See details»
GammaDelta Therapeutics - PitchBook
GammaDelta Therapeutics General Information Description. Developer of immunotherapies designed to treat cancer and auto-immune diseases. The company's immunotherapies use t-cells and have the potential to make a …See details»
Overview, News & Similar companies - ZoomInfo.com
Who is GammaDelta Therapeutics. GammaDelta Therapeutics is working to develop improved immunotherapies for cancer and other serious diseases. The company's research and …See details»
GammaDelta Therapeutics - Craft
GammaDelta Therapeutics is a company committed to transforming the treatment of patients living with hematological and solid cancers. It develops cancer therapy based on the body’s …See details»
Takeda and GammaDelta Therapeutics Announce Collaboration to …
May 9, 2017 Contact GammaDelta Therapeutics Ltd: Raj Mehta Director of Intellectual Property, Alliance Management and Business Development Paolo Paoletti, MD CEO T: +44 (0) 207 691 …See details»
Takeda to Acquire GammaDelta Therapeutics to ... - Takeda …
Oct 27, 2021 Takeda Pharmaceutical Company Limited (“Takeda”) today announced the exercise of its option to acquire GammaDelta Therapeutics Limited (“GammaDelta”), a …See details»
GammaDelta Therapeutics Receives FDA Clearance of IND
May 20, 2021 GammaDelta Therapeutics, a company focussed on exploiting the unique properties of gamma delta T cells for immunotherapy, announced the U.S. Food and Drug …See details»
GammaDelta Therapeutics receives FDA clearance of …
Jun 29, 2021 GammaDelta Therapeutics has received US FDA clearance for the Investigational New Drug (IND) application for the Company’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy, GDX012, to be investigated as …See details»
GammaDelta Therapeutics initiates first-in-human Phase 1 trial of ...
London, UK, 15 Sept 2021: GammaDelta Therapeutics Ltd. (GDT), a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for …See details»
GammaDelta Therapeutics Initiates First-in-Human Phase 1 Trial of ...
Sep 15, 2021 GammaDelta Therapeutics Ltd. (GDT), a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for caSee details»
GammaDelta Therapeutics Receives FDA Clearance of IND …
May 20, 2021 First-in-human clinical study for Acute Myeloid Leukaemia expected to begin later in 2021; FDA also granted orphan drug designation to GDX012 for the treatment of Acute …See details»
Takeda to Acquire GammaDelta Therapeutics to Accelerate …
Oct 27, 2021 Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire GammaDelta Therapeutics Limited (“GammaDelta”), a company focused on exploiting …See details»
Takeda to Acquire GammaDelta Therapeutics to Accelerate …
Oct 27, 2021 Takeda exercised its option to acquire GammaDelta Therapeutics, expanding Takeda's immuno-oncology and innate immune cell therapy portfolio.See details»
GammaDelta Therapeutics Initiates First-in-Human Phase 1 Trial of ...
Sep 17, 2021 LONDON – GammaDelta Therapeutics Ltd. (GDT), a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for …See details»
Stock Market News - MarketScreener.com
May 20, 2021 GammaDelta Therapeutics (“GammaDelta”), a company focussed on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy, today announced the …See details»
GammaDelta Therapeutics initiates first-in-human phase 1 trial of ...
London, UK, 15 Sept 2021: GammaDelta Therapeutics Ltd. (GDT), a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for …See details»
Cancer immunotherapy with γδ T cells: many paths ahead of us
Major receptor–ligand interactions between Vδ2/non-Vδ2 γδ T cells and tumor cells/antigen-presenting cells. Left side: The best characterized ligands for the human Vγ9Vδ2 TCR are …See details»